
FDA Issues Second Complete Response Letter for Deramiocel in Duchenne Muscular Dystrophy
Key Takeaways
- A second CRL determined deramiocel’s dataset did not meet the FDA threshold for substantial evidence of effectiveness, with additional undisclosed clinical deficiencies cited.
- HOPE-3 randomized 106 advanced DMD patients and met its prespecified primary endpoint, showing a 4.55% least-squares mean advantage in PUL2.0 change at 12 months.
The FDA issued a second complete response letter for deramiocel in Duchenne muscular dystrophy, citing insufficient evidence of effectiveness from the phase 3 HOPE-3 trial.
The FDA has issued a second complete response letter (CRL) for deramiocel (Capricor Therapeutics), an allogeneic cardiosphere-derived cell therapy, declining to approve the company’s resubmitted biologics license application (BLA) in Duchenne muscular dystrophy (DMD).1 The rejection came 2 days before the November 22 action date. It caps a review that was extended by 3 months after the agency’s advisory panel voted that the data did not support the therapy’s effectiveness in DMD cardiomyopathy.2
According to Capricor, the letter states that the FDA does not consider the data sufficient to establish substantial evidence of effectiveness. It also cites certain other clinical deficiencies, which the company did not describe.1 FDA reviewers have disputed whether HOPE-3 met its prespecified end points under the trial’s original statistical analysis plan.3
“We are deeply disappointed for the boys and young men living with Duchenne and their families,” Linda Marbán, PhD, chief executive officer of Capricor, in the said in a statement.1 “Deramiocel has been studied in two randomized, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, both of which met their primary endpoints. We stand behind the rigor of our clinical program and the integrity of our data, and we believe the data support approval.”
The application rests on the phase 3 HOPE-3 trial (NCT05126758), in which deramiocel slowed decline on the Performance of the Upper Limb version 2.0 (PUL2.0) by 54% vs placebo at 12 months.4,5 “A nearly 54 percent slowing of skeletal muscle disease progression is extraordinary in Duchenne and directly linked to maintaining independence and quality of life in the most severely affected patients with greatest unmet need,” Craig McDonald, MD, distinguished professor of physical medicine and rehabilitation and pediatrics at UC Davis Health and national principal investigator of HOPE-3, when
HOPE-3 Data Behind the Application
HOPE-3 randomly assigned 106 participants aged 10 years and older with advanced DMD to deramiocel (n = 54) or placebo (n = 52), given as 150 million cells intravenously every 3 months for 4 doses.4-6 In the peer-reviewed Lancet report, the least-squares mean percentage change in total PUL2.0 score at 12 months favored deramiocel by 4.55% (95% CI, 0.47 to 8.63; P = .029).5 Average age at baseline was about 15 years. All participants were on stable corticosteroids, and more than 75% had a clinical diagnosis of cardiomyopathy.4
On the key secondary end point, deramiocel slowed decline in left ventricular ejection fraction (LVEF) on cardiac MRI by 91% vs placebo (n = 83; P = .041). Capricor has not published a CI for this result.3,4 The company described the safety profile as consistent with prior experience. The Lancet abstract reported safety similar to placebo but did not give event counts.4,5
Newer data presented at the 2026 World Muscle Society (WMS) Congress showed that participants who switched from placebo to deramiocel in year 2 declined 1.56 points less on PUL2.0 than during their placebo year. That is a 76% slowing in an open-label, cross-phase comparison.7
Advisory Committee and Refined Indication
At its July 2026 meeting, the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee
Capricor then filed a major amendment with 24-month open-label extension data, additional robustness analyses, and an integrated efficacy summary across HOPE-2 and HOPE-3. The company proposed a refined indication focused on upper limb impairment in patients older than 9 years. The FDA’s Center for Biologics Evaluation and Research (CBER) then
What Comes Next
Capricor said it is reviewing the letter carefully and will share next steps once it has completed its evaluation.1 The company noted that it has begun regulatory engagement in Europe and Japan.1,7
A Long Road to a Decision
Deramiocel’s path to this decision began with a
HOPE-3, which had cleared an
REFERENCES
1. Capricor Therapeutics provides regulatory update on deramiocel BLA for Duchenne muscular dystrophy. News release. Capricor Therapeutics. November 20, 2026. Accessed November 20, 2026. https://www.capricor.com/investors/news-events/press-releases/detail/360/capricor-therapeutics-provides-regulatory-update-on
2. Capricor Therapeutics provides update on FDA advisory committee meeting for deramiocel. News release. Capricor Therapeutics. July 30, 2026. Accessed November 20, 2026. https://www.biospace.com/press-releases/capricor-therapeutics-provides-update-on-fda-advisory-committee-meeting-for-deramiocel
3. US Food and Drug Administration. FDA briefing document: BLA 125842, deramiocel. Cellular, Tissue, and Gene Therapies Advisory Committee meeting. July 29, 2026. Accessed November 20, 2026. https://www.fda.gov/media/193839/download
4. Capricor Therapeutics announces positive topline results from pivotal phase 3 HOPE-3 study of deramiocel in Duchenne muscular dystrophy. News release. Capricor Therapeutics. December 3, 2025. Accessed November 20, 2026. https://www.capricor.com/investors/news-events/press-releases/detail/331/capricor-therapeutics-announces-positive-topline-results
5. McDonald CM, Villa C, Soslow JH, et al; HOPE-3 Investigators. Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026;408(10556):721-733. doi:10.1016/S0140-6736(26)01385-1
6. Capricor Therapeutics announces continuation of phase 3 HOPE-3 trial of CAP-1002 in Duchenne muscular dystrophy based on completion of interim futility analysis. News release. Capricor Therapeutics. December 11, 2023. Accessed November 20, 2026. https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001558370-23-019717/capr-20231211xex99d1.htm
7. Capricor Therapeutics reports third quarter 2026 financial results and provides corporate update. News release. Capricor Therapeutics. November 10, 2026. Accessed November 20, 2026. https://finviz.com/news/420500/capricor-therapeutics-reports-third-quarter-2026-financial-results-and-provides-corporate-update
8. Capricor Therapeutics announces extension of PDUFA target action date as FDA continues review of deramiocel BLA. News release. Capricor Therapeutics. August 24, 2026. Accessed November 20, 2026. https://finviz.com/news/384886/capricor-therapeutics-announces-extension-of-pdufa-target-action-date-as-fda-continues-review-of-deramiocel-bla
9. Capricor Therapeutics reports third quarter 2024 financial results and provides corporate update. News release. Capricor Therapeutics. November 13, 2024. Accessed November 20, 2026. https://www.capricor.com/investors/news-events/press-releases/detail/300/capricor-therapeutics-reports-third-quarter-2024-financial
10. Capricor Therapeutics completes submission of biologics license application to the U.S. FDA for deramiocel for the treatment of Duchenne muscular dystrophy. News release. Capricor Therapeutics. January 2, 2025. Accessed November 20, 2026. https://www.capricor.com/investors/news-events/press-releases/detail/303/capricor-therapeutics-completes-submission-of-biologics
11. Capricor Therapeutics announces completion of mid-cycle review meeting with FDA on deramiocel for the treatment of Duchenne muscular dystrophy cardiomyopathy. News release. Capricor Therapeutics. May 5, 2025. Accessed November 20, 2026. https://www.capricor.com/investors/news-events/press-releases/detail/311/capricor-therapeutics-announces-completion-of-mid-cycle
12. Capricor Therapeutics provides regulatory update on deramiocel BLA for Duchenne muscular dystrophy. News release. Capricor Therapeutics. July 11, 2025. Accessed November 20, 2026. https://www.capricor.com/investors/news-events/press-releases/detail/319/capricor-therapeutics-provides-regulatory-update-on
13. Capricor Therapeutics provides regulatory update on deramiocel BLA following FDA review of HOPE-3 topline data. News release. Capricor Therapeutics. January 20, 2026. Accessed November 20, 2026. https://www.capricor.com/investors/news-events/press-releases/detail/335/capricor-therapeutics-provides-regulatory-update-on
14. US Food and Drug Administration. BLA 125842 deramiocel (CAP-1002): clinical overview. Cellular, Tissue, and Gene Therapies Advisory Committee meeting. July 29, 2026. Accessed November 20, 2026. https://www.fda.gov/media/193912/download
15. Capricor Therapeutics announces establishment of new PDUFA date for deramiocel BLA. News release. Capricor Therapeutics. March 10, 2026. Accessed November 20, 2026. https://www.biospace.com/press-releases/capricor-therapeutics-announces-establishment-of-new-pdufa-date-for-deramiocel-bla
Related to this article








